Sernova Corp. announced that, as part of a planned leadership succession process, and after a successful 13-year tenure leading the Company through the development of its pioneering Cell Pouch SystemTM and ensuing growth, Dr. Philip Toleikis, President and Chief Executive Officer will be appointed Sernova's Chief Technology Officer (CTO). To achieve a seamless transition and continue progress on all Company activities, Dr. Toleikis will remain in the CEO role during the search period and continue to work closely with Executive Chair, Frank Holler.

Mr. Holler will, in particular, take a leadership role and work closely with Dr. Toleikis in advancing Sernova's business development and corporate finance activities during the search period. Dr. Philip Toleikis joined Sernova in 2009. Under his leadership, the Company has achieved remarkable interim results in its ongoing Phase 1/2 type 1 diabetes (T1D) clinical trial, expanded the capabilities of its CPS platform via technology acquisitions, and significantly bolstered its balance sheet.